 Benedetto Mungo
Concepts (196)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adenocarcinoma | 9 | 2025 | 940 | 3.320 |
Why?
| | Esophageal Neoplasms | 15 | 2025 | 321 | 2.830 |
Why?
| | Stomach Neoplasms | 3 | 2025 | 122 | 2.430 |
Why?
| | Esophagectomy | 15 | 2024 | 131 | 2.230 |
Why?
| | Databases, Factual | 11 | 2025 | 1357 | 1.700 |
Why?
| | Lymph Node Excision | 3 | 2024 | 171 | 1.310 |
Why?
| | Robotic Surgical Procedures | 2 | 2022 | 130 | 1.110 |
Why?
| | Neoadjuvant Therapy | 7 | 2025 | 404 | 1.080 |
Why?
| | Time-to-Treatment | 3 | 2025 | 205 | 1.070 |
Why?
| | Thoracic Surgery, Video-Assisted | 3 | 2016 | 43 | 1.060 |
Why?
| | Pancreatic Neoplasms | 4 | 2024 | 938 | 1.040 |
Why?
| | Laparoscopy | 6 | 2024 | 466 | 1.010 |
Why?
| | Chemoradiotherapy | 2 | 2024 | 225 | 0.900 |
Why?
| | Gallbladder Neoplasms | 1 | 2024 | 23 | 0.890 |
Why?
| | Metastasectomy | 1 | 2024 | 20 | 0.890 |
Why?
| | Survival Rate | 8 | 2025 | 1972 | 0.890 |
Why?
| | Induction Chemotherapy | 1 | 2024 | 76 | 0.880 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2024 | 63 | 0.870 |
Why?
| | Peritoneal Neoplasms | 1 | 2024 | 93 | 0.840 |
Why?
| | Postoperative Complications | 14 | 2024 | 2654 | 0.830 |
Why?
| | Retrospective Studies | 31 | 2025 | 15657 | 0.750 |
Why?
| | Carcinoma, Pancreatic Ductal | 3 | 2024 | 289 | 0.730 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2025 | 1692 | 0.700 |
Why?
| | Social Determinants of Health | 1 | 2025 | 267 | 0.700 |
Why?
| | Anastomosis, Surgical | 4 | 2024 | 153 | 0.700 |
Why?
| | Liver Neoplasms | 2 | 2024 | 786 | 0.640 |
Why?
| | Aged | 30 | 2025 | 23961 | 0.630 |
Why?
| | Hernia, Hiatal | 4 | 2017 | 35 | 0.600 |
Why?
| | Herniorrhaphy | 3 | 2014 | 60 | 0.550 |
Why?
| | Middle Aged | 27 | 2025 | 33479 | 0.530 |
Why?
| | Colectomy | 1 | 2017 | 100 | 0.520 |
Why?
| | Pneumonectomy | 2 | 2016 | 152 | 0.520 |
Why?
| | Minimally Invasive Surgical Procedures | 2 | 2023 | 179 | 0.470 |
Why?
| | Colonic Neoplasms | 1 | 2017 | 258 | 0.460 |
Why?
| | Follow-Up Studies | 8 | 2024 | 5131 | 0.450 |
Why?
| | Length of Stay | 10 | 2017 | 1215 | 0.420 |
Why?
| | Gastrectomy | 2 | 2025 | 126 | 0.420 |
Why?
| | Lung Neoplasms | 2 | 2016 | 2526 | 0.370 |
Why?
| | Male | 30 | 2025 | 67762 | 0.370 |
Why?
| | Female | 34 | 2025 | 73304 | 0.360 |
Why?
| | Pancreatectomy | 2 | 2024 | 253 | 0.350 |
Why?
| | Treatment Outcome | 17 | 2024 | 10811 | 0.330 |
Why?
| | United States | 15 | 2025 | 14841 | 0.330 |
Why?
| | Humans | 41 | 2025 | 137585 | 0.330 |
Why?
| | Lymph Nodes | 3 | 2024 | 491 | 0.320 |
Why?
| | Prognosis | 4 | 2024 | 4030 | 0.300 |
Why?
| | Esophageal Stenosis | 2 | 2024 | 54 | 0.290 |
Why?
| | Operative Time | 4 | 2015 | 145 | 0.270 |
Why?
| | Lymphatic Metastasis | 3 | 2024 | 352 | 0.260 |
Why?
| | Stomach | 3 | 2024 | 110 | 0.260 |
Why?
| | Esophageal Diseases | 2 | 2017 | 28 | 0.260 |
Why?
| | Patient Readmission | 3 | 2017 | 697 | 0.250 |
Why?
| | Hepatectomy | 2 | 2024 | 251 | 0.240 |
Why?
| | Anastomotic Leak | 3 | 2024 | 41 | 0.240 |
Why?
| | Neoplasm Staging | 3 | 2025 | 1389 | 0.240 |
Why?
| | Thoracic Surgery | 2 | 2017 | 132 | 0.230 |
Why?
| | Biliary Tract Neoplasms | 1 | 2025 | 30 | 0.230 |
Why?
| | Adult | 13 | 2024 | 37929 | 0.230 |
Why?
| | Pancreaticoduodenectomy | 2 | 2024 | 164 | 0.230 |
Why?
| | Obesity | 2 | 2015 | 2992 | 0.230 |
Why?
| | Chemotherapy, Cancer, Regional Perfusion | 1 | 2024 | 28 | 0.220 |
Why?
| | General Surgery | 2 | 2017 | 173 | 0.220 |
Why?
| | Esophagogastric Junction | 1 | 2024 | 51 | 0.220 |
Why?
| | Quality Improvement | 4 | 2017 | 1178 | 0.210 |
Why?
| | Ischemic Preconditioning | 1 | 2024 | 41 | 0.210 |
Why?
| | Aged, 80 and over | 10 | 2017 | 7635 | 0.210 |
Why?
| | Risk Factors | 9 | 2024 | 10388 | 0.210 |
Why?
| | Cholangiocarcinoma | 1 | 2024 | 104 | 0.200 |
Why?
| | Bile Duct Neoplasms | 1 | 2024 | 124 | 0.200 |
Why?
| | Specialties, Surgical | 1 | 2023 | 75 | 0.200 |
Why?
| | Pancreatic Fistula | 1 | 2022 | 30 | 0.190 |
Why?
| | Receptor, ErbB-2 | 1 | 2025 | 341 | 0.190 |
Why?
| | Molecular Targeted Therapy | 1 | 2025 | 411 | 0.180 |
Why?
| | Natural Orifice Endoscopic Surgery | 2 | 2012 | 34 | 0.180 |
Why?
| | Logistic Models | 6 | 2017 | 2074 | 0.180 |
Why?
| | Combined Modality Therapy | 1 | 2024 | 1236 | 0.180 |
Why?
| | Socioeconomic Factors | 1 | 2025 | 1289 | 0.170 |
Why?
| | Body Composition | 1 | 2024 | 684 | 0.170 |
Why?
| | Hospital Mortality | 5 | 2017 | 911 | 0.160 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2016 | 683 | 0.160 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2020 | 80 | 0.160 |
Why?
| | Surgeons | 1 | 2023 | 297 | 0.160 |
Why?
| | Reoperation | 3 | 2016 | 573 | 0.150 |
Why?
| | Thoracotomy | 2 | 2016 | 75 | 0.150 |
Why?
| | Protein Kinase Inhibitors | 1 | 2025 | 916 | 0.150 |
Why?
| | Neoplasm Invasiveness | 1 | 2020 | 510 | 0.150 |
Why?
| | Multivariate Analysis | 3 | 2017 | 1509 | 0.150 |
Why?
| | Esophagoplasty | 1 | 2016 | 2 | 0.130 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2016 | 59 | 0.130 |
Why?
| | Esophageal Mucosa | 1 | 2016 | 22 | 0.130 |
Why?
| | Body Mass Index | 2 | 2015 | 2389 | 0.130 |
Why?
| | Optical Imaging | 1 | 2016 | 64 | 0.130 |
Why?
| | Conversion to Open Surgery | 1 | 2016 | 16 | 0.130 |
Why?
| | Specialization | 1 | 2017 | 144 | 0.120 |
Why?
| | Lymphatic Vessels | 1 | 2016 | 64 | 0.120 |
Why?
| | Pleurodesis | 1 | 2014 | 3 | 0.110 |
Why?
| | Thoracic Diseases | 1 | 2014 | 14 | 0.110 |
Why?
| | Talc | 1 | 2014 | 9 | 0.110 |
Why?
| | Thinness | 1 | 2015 | 91 | 0.110 |
Why?
| | Hepatic Artery | 1 | 2014 | 62 | 0.110 |
Why?
| | Age Factors | 4 | 2014 | 3295 | 0.110 |
Why?
| | Tissue Adhesions | 1 | 2014 | 32 | 0.110 |
Why?
| | Matched-Pair Analysis | 1 | 2014 | 39 | 0.110 |
Why?
| | Respiration Disorders | 1 | 2014 | 77 | 0.110 |
Why?
| | Endometriosis | 1 | 2014 | 51 | 0.110 |
Why?
| | Thoracic Surgical Procedures | 1 | 2014 | 73 | 0.110 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2014 | 91 | 0.110 |
Why?
| | Standard of Care | 1 | 2014 | 72 | 0.100 |
Why?
| | Leukocyte Count | 1 | 2014 | 329 | 0.100 |
Why?
| | Digestive System Surgical Procedures | 1 | 2014 | 106 | 0.100 |
Why?
| | Postoperative Period | 1 | 2014 | 342 | 0.100 |
Why?
| | Esophageal Achalasia | 1 | 2013 | 30 | 0.100 |
Why?
| | Health Services Needs and Demand | 1 | 2014 | 273 | 0.100 |
Why?
| | Quality Indicators, Health Care | 1 | 2015 | 307 | 0.100 |
Why?
| | Gastroscopes | 1 | 2012 | 3 | 0.100 |
Why?
| | Sarcoma | 1 | 2014 | 188 | 0.100 |
Why?
| | Jejunum | 1 | 2012 | 31 | 0.090 |
Why?
| | Surgical Stapling | 1 | 2012 | 15 | 0.090 |
Why?
| | Urinary Tract Infections | 1 | 2014 | 188 | 0.090 |
Why?
| | Rothmund-Thomson Syndrome | 1 | 2011 | 1 | 0.090 |
Why?
| | Surgical Wound Infection | 1 | 2014 | 307 | 0.090 |
Why?
| | Fundoplication | 3 | 2017 | 53 | 0.090 |
Why?
| | Guideline Adherence | 1 | 2015 | 556 | 0.090 |
Why?
| | Catheterization | 1 | 2011 | 179 | 0.090 |
Why?
| | Ileum | 1 | 2011 | 119 | 0.080 |
Why?
| | Venous Thromboembolism | 1 | 2014 | 316 | 0.080 |
Why?
| | Neoplasms | 2 | 2015 | 2671 | 0.080 |
Why?
| | Rectum | 1 | 2011 | 185 | 0.080 |
Why?
| | Decision Support Techniques | 1 | 2013 | 421 | 0.080 |
Why?
| | Weight Loss | 1 | 2014 | 787 | 0.070 |
Why?
| | Constriction, Pathologic | 2 | 2024 | 245 | 0.070 |
Why?
| | Time Factors | 4 | 2024 | 6828 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2015 | 1587 | 0.070 |
Why?
| | Biomarkers | 2 | 2014 | 4149 | 0.060 |
Why?
| | Pandemics | 2 | 2025 | 1639 | 0.060 |
Why?
| | Feasibility Studies | 3 | 2016 | 956 | 0.060 |
Why?
| | Chi-Square Distribution | 2 | 2016 | 530 | 0.060 |
Why?
| | Anthropometry | 1 | 2024 | 213 | 0.050 |
Why?
| | Young Adult | 3 | 2015 | 13209 | 0.050 |
Why?
| | Odds Ratio | 2 | 2016 | 1070 | 0.050 |
Why?
| | Lung | 1 | 2014 | 4060 | 0.050 |
Why?
| | Risk Assessment | 2 | 2024 | 3457 | 0.040 |
Why?
| | Adolescent | 3 | 2015 | 21513 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2024 | 635 | 0.040 |
Why?
| | Models, Animal | 2 | 2012 | 384 | 0.040 |
Why?
| | Equipment Design | 2 | 2012 | 522 | 0.040 |
Why?
| | Comorbidity | 2 | 2014 | 1622 | 0.040 |
Why?
| | Swine | 2 | 2012 | 775 | 0.040 |
Why?
| | Incidence | 2 | 2016 | 2804 | 0.040 |
Why?
| | Biomarkers, Tumor | 1 | 2025 | 1276 | 0.030 |
Why?
| | Gastric Fundus | 1 | 2017 | 3 | 0.030 |
Why?
| | Indocyanine Green | 1 | 2016 | 24 | 0.030 |
Why?
| | Maryland | 1 | 2016 | 60 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2024 | 3556 | 0.030 |
Why?
| | Sierra Leone | 1 | 2014 | 2 | 0.030 |
Why?
| | Baltimore | 1 | 2015 | 60 | 0.030 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2015 | 43 | 0.030 |
Why?
| | Breast Diseases | 1 | 2014 | 22 | 0.030 |
Why?
| | Fluorescent Dyes | 1 | 2016 | 321 | 0.030 |
Why?
| | Esophagoscopy | 1 | 2016 | 209 | 0.030 |
Why?
| | Uterine Diseases | 1 | 2014 | 15 | 0.030 |
Why?
| | Gastroplasty | 1 | 2014 | 30 | 0.030 |
Why?
| | Hospital Charges | 1 | 2013 | 44 | 0.030 |
Why?
| | Survival Analysis | 1 | 2016 | 1325 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2014 | 686 | 0.030 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2014 | 212 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2016 | 1266 | 0.020 |
Why?
| | Neoplasm, Residual | 1 | 2013 | 133 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2014 | 565 | 0.020 |
Why?
| | Remission Induction | 1 | 2013 | 288 | 0.020 |
Why?
| | Cerebrovascular Disorders | 1 | 2013 | 96 | 0.020 |
Why?
| | Developing Countries | 1 | 2014 | 307 | 0.020 |
Why?
| | Intubation, Intratracheal | 1 | 2014 | 257 | 0.020 |
Why?
| | Malnutrition | 1 | 2013 | 83 | 0.020 |
Why?
| | Diagnostic Imaging | 1 | 2014 | 332 | 0.020 |
Why?
| | Gastroesophageal Reflux | 1 | 2014 | 234 | 0.020 |
Why?
| | Pilot Projects | 1 | 2016 | 1710 | 0.020 |
Why?
| | Recurrence | 1 | 2014 | 1060 | 0.020 |
Why?
| | Disease Management | 1 | 2015 | 628 | 0.020 |
Why?
| | Colonic Diseases | 1 | 2011 | 33 | 0.020 |
Why?
| | Hypothyroidism | 1 | 2011 | 72 | 0.020 |
Why?
| | Health Status | 1 | 2016 | 792 | 0.020 |
Why?
| | Overweight | 1 | 2015 | 558 | 0.020 |
Why?
| | Anal Canal | 1 | 2011 | 97 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2014 | 645 | 0.020 |
Why?
| | Kidney Diseases | 1 | 2013 | 408 | 0.020 |
Why?
| | Pneumonia | 1 | 2014 | 639 | 0.020 |
Why?
| | Patient Discharge | 1 | 2015 | 897 | 0.020 |
Why?
| | Prevalence | 1 | 2014 | 2734 | 0.020 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 1040 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2014 | 5472 | 0.010 |
Why?
| | Cohort Studies | 1 | 2013 | 5742 | 0.010 |
Why?
| | Heart Failure | 1 | 2013 | 2236 | 0.010 |
Why?
| | Animals | 2 | 2012 | 36940 | 0.010 |
Why?
| | Infant | 1 | 2011 | 9465 | 0.010 |
Why?
| | Child | 1 | 2014 | 21935 | 0.010 |
Why?
|
|
Mungo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|